Hot

ADT1743-Anti-PD-1-CTLA-4-Bispecific Antibody-Alpha Lifetech.png

ADT1743-Human Anti-PD-1xCTLA-4 Bispecific Antibody

Catalog Number ADT1743
Host CHO Cells
Species Human
Target PD-1xCTLA-4
Application FuncS

PD-1, an immune checkpoint protein encoded by the PDCD1 gene, plays a crucial role in inhibiting T-cell activity, making it a key target in cancer immunotherapy. Similarly, CTLA-4, a T cell surface receptor, negatively regulates immune responses. Antibody drugs are designed to enhance anti-tumor immune responses by targeting these pathways.

At Alpha Lifetech, we specialize in providing high-quality bispecific antibody products and comprehensive bispecific antibody development services. Trust us to accelerate your research.

COA datasheet MSDS

Products Categories

ADT1090-Bevacizumab Biosimilar: Anti-Human VEGFA mab- Res...

ADT1005-Abciximab Biosimilar: (ITGA2B_ITGB3)- Research Grade

ADT1110-Cabiralizumab Biosimilar: Anti-CSF1R mab- Researc...

ADT1171-Dezamizumab Biosimilar: Anti-APCS mab- Research G...

ADT1193-Edobacomab Biosimilar: Anti- Endotoxin mab- Resea...

ALP64505-Recombinant Human CD24 Protein, mFc Tag

ALP64510-Recombinant Cynomolgus Monkey SIRP alpha/CD172a ...

ALP64533-Recombinant Mouse Siglec-15 /CD33L3 Protein, His...

ALP64562-Recombinant Rhesus Macaque CD160 Protein, Fc Tag

ALP64567-Recombinant Rabbit CD86 Protein, His Tag

0102030405

recommended service

quick links

+1 609-736-0910
info@alphalifetech.com
90 State Street, STE 700 Office 40, Albany, NY 12207 United States

Product Background Product Specification FAQ

Product Background

PD1, Programmed cell death 1, PDCD1 (CD279, hSLE 1, PD-1, SLEB 2), a member of the CD28 superfamily, is a type I transmembrane protein composed of 268 amino acids. It was discovered by a Japanese professor in 1992 and is expressed on the surface of immune cells such as T cells and B cells. However, T cells hardly expressed PD-1 when not activated, and only after T-cell activation was the PD-1 expressed on the T-cell surface.

CTLA-4, a T cell surface receptor, negatively regulates immune response, and antibody drugs are used to enhance anti-tumor immune response.

Product Specification

Catalog Number	ADT1743
Product Name	ADT1743-Human Anti-PD-1xCTLA-4 Bispecific Antibody
Isotype	Human IgG1-kappa
Clonity	Monoclonal
Alternate Names Human Anti-PD-1 mAb, Anti-PD-1 Monoclonal Antibody, PD-1 recombinant antibody, Anti-PD-1 Bispecific Antibody, Human Anti-CTLA-4 mAb, CTLA-4 recombinant antibody, Anti-CTLA-4 Monoclonal Antibody, Anti-CTLA-4 Bispecific Antibody
Official Symbol	PD-1xCTLA-4
Target 1	PD-1
Gene ID 1	5133
Target 2	CTLA-4
Gene ID 2	1493
Species	Human
Drug Name	Cadonilimab
Endotoxin	<1EU/mg. Determined by the LAL method.
Sterility	0.2 μM filtered.
Expression Host	CHO Cells
CAS Number	2394841-59-7
Size	1mg,5mg,50mg,100mg
Research Area	Cancer
Application	FuncS
Purity	>90%
Concentration	Batch dependent
Buffer	Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives
Recommended Dilution Buffer	ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives.
Storage	2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage.
Shipping Condition	Shipped on ice packs.
Protocol Information	Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment.
Note	For Research Use Only!
Reference 1. Freeman et al. (2000). J Exp Med. DOI: 10.1084/jem.192.7.1027 2. Topalian et al. (2012). NEJM. DOI: 10.1056/NEJMoa1200690 3. Leach et al. (1996). Science. DOI: 10.1126/science.272.5260.1737 4. Hodi et al. (2010). NEJM. DOI: 10.1056/NEJMoa1003466

FAQ

+ -
What are PD-1 and CTLA-4?

PD-1 and CTLA-4 are immune checkpoint proteins that suppress T-cell activity. Dual blockade enhances anti-tumor immune responses.
+ -
How can I obtain COA of the reagent that I received?

Please contact us via email info@alphalifetech.com for detailed information about the product.
+ -
Why combine PD-1 and CTLA-4 targeting?

This bispecific antibody amplifies immune activation, potentially improving efficacy compared to single-checkpoint inhibitors.
+ -
Are BsAbs clinically superior to monoclonal antibodies (MoAbs)?

BsAbs are clinically superior to monoclonal antibodies (MoAbs) and have been widely used in tumor immunotherapy and the treatment of other diseases (such as hemophilia A, diabetes, Alzheimer's disease, and ophthalmic diseases).